(1) The Department of Insurance shall consult with the council and the task force to monitor emerging coverage barriers related to rare disease therapies.
(2) The council may accept and review written complaints from patients, providers, or advocacy organizations regarding alternative funding practices and shall refer substantiated complaints to the Department of Insurance for investigation.